Benitec Biopharma (BNTC)

Executive Summary

Benitec Biopharma is a clinical-stage biotechnology company leveraging its proprietary DNA-directed RNA interference (ddRNAi) platform to develop durable, single-administration gene silencing therapies. The company's lead program targets oculopharyngeal muscular dystrophy (OPMD), a rare, progressive muscle disorder with high unmet need. Benitec also completed a Phase 2 trial of BB-401 for head and neck squamous cell carcinoma, though the primary focus is now on OPMD. With a unique approach that combines gene therapy and RNA interference, Benitec aims to provide a one-time treatment that could significantly alter the disease course. The company is publicly traded (NASDAQ: BNTC) with a market valuation around $396 million as of early 2026.

Upcoming Catalysts (preview)

• 2026 Q3Interim Data from OPMD Phase 1/2 Trial40% success
• 2026 Q4FDA Type C Meeting or Regulatory Guidance for OPMD Program70% success
• 2026 Q3Financing Update to Extend Cash Runway80% success